Hologic closes acquisition of Mobidiag

June 17, 2021
MARLBOROUGH, Mass.–(BUSINESS WIRE)– Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of Mobidiag Oy, an innovator in near-patient, acute care molecular diagnostic testing, for an enterprise value of approximately $808 million.

“Closing the acquisition of Mobidiag enables us to become a broader, more diversified global diagnostics leader,” said Jan Verstreken, group president, international at Hologic. “Together, we can accelerate development and adoption of Mobidiag’s innovative products globally and drive Hologic’s growth.”

Continue Reading

Mobidiag to Be Acquired by Hologic, Innovator in Women’s Health Diagnostic Testing, for Approximately €668 Million

Transaction Will Accelerate Global Growth of Mobidiag’s Differentiated Molecular Platform, which Offers Ease of Use, Multiplex Capability and Rapid Turnaround Time —

ESPOO, Finland, April 08, 2021 — Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, announced today that it has signed a definitive agreement to be acquired by Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, for an enterprise value of approximately €668 million ($795 million).  This includes a cash payment of approximately €600 million ($714 million) for Mobidiag’s equity, and net debt of approximately €68 million ($81 million).

Continue Reading

Mobidiag receives CE-IVD for Amplidiag® RESP-4 for simultaneous detection of COVID-19, Flu A, Flu B and RSV

  • Real-time PCR-based test enables high-throughput reliable detection of most prevalent respiratory infections, including COVID-19
  • One single test determines the virus responsible for patient symptoms, guiding treatment decisions and rapid isolation strategy if required

FINLAND, Espoo, March 1st, 2021 – Mobidiag Ltd. today announces that it has received CE-IVD marking for its Amplidiag® RESP-4 molecular diagnostic test for the rapid and simultaneous detection of some of the most prevalent respiratory viruses: SARS-CoV-2 (responsible for COVID-19 infection), Influenza A, Influenza B and RSV.

These viruses present similar symptoms, making it difficult for physicians to determine accurately which virus a patient has. The Amplidiag® RESP-4 assay can rapidly and simultaneously determine an accurate diagnosis from one patient sample using nasopharyngeal swabs, helping to guide clinicians to the relevant treatment decision for each patient. The test runs on the Mobidiag Amplidiag® Easy platform, which provides clinicians with an optimized sample screening process, with automated DNA/RNA extraction and PCR plate setup. Based on well-established high-throughput PCR technology, the platform can process 46 samples in approximately three hours.

Continue Reading

Amplidiag® and Novodiag® solutions now available through distribution in Norway

Mobidiag Ltd. today announces that it has signed an agreement with XboXLab for the distribution of its molecular diagnostic products Amplidiag® and Novodiag® in Norway.

We are very pleased to expand our distribution network and be able to provide Norwegian clinical laboratories with our innovative molecular diagnostic solutions.

For more information, please contact :
Henning Jansen
+47 40 33 00 11
henning.jansen@xboxlab.no
www.xboxlab.se

Mobidiag products are also available throughout Europe and the Middle East. Visit our Distributor page to learn more.

Continue Reading

Mobidiag COVID-19 test performances not affected by variants from United Kingdom, South Africa or Brazil

2020 was an unprecedented year as the world faced the unexpected and rapid spread of coronavirus. As the pandemic extends into 2021, we have been witnessing specific new variants spreading rapidly in the United Kingdom, South Africa and Brazil.

These new variants will however not impact the performance of our molecular assays Amplidiag COVID-19, nor Novodiag COVID-19, which utilise targets for N gene and Orf1ab. The new coronavirus variants potentially have an impact on assays using the S protein as a target, which is not the case for Mobidiag tests. At Mobidiag, it is part of our routine post-market surveillance to monitor for new coronavirus variants and developments to ensure that the performance of our assays is always suitable for the market.

If you have any questions, please do not hesitate to contact us:
By email: sales@mobidiag.com

By phone:
+358 10 5050 770
+44 333 305 7506
+33 1 55 25 17 00

Continue Reading

Journal of Clinical Microbiology

2020 Jan 29. doi:10.1128/JCM.01787-19
Diagnostic accuracy of a non-invasive test for the detection of Helicobacter pylori and resistance to clarithromycin in stool by Real-Time PCR Amplidiag® H. pylori + ClariR assay
Pichon M, Pichard B, Barrioz T, Plouzeau C, Croquet V, Fotsing G, Chéron A, Vuillemin É, Wangermez M, Haineaux P-A, Vasseur P, Thiebault Q, Lefèvre C, Singly A, Cremniter J, Broutin L, Michaud A, Silvain C, Burucoa C
Learn more about Amplidiag® H. pylori + ClariR assay

Continue Reading

Mobidiag offers complete diagnostic solution for the detection of novel coronavirus infections with both PCR and antibody tests

  • CE-IVD marked molecular diagnostic tests on the Novodiag and Amplidiag platforms for rapid detection of COVID-19 infections to support decisions for efficient patient isolation, treatment and release
  • Antibody test for detection of past COVID-19 infections
  • Secure supply chain and in-house manufacturing capabilities to meet demand
  • Continue Reading

    Mobidiag in the news with an interview with partner AMETEK Haydon Kerk Pittman Motion Solutions

    Thanks to the support and involvement of our trusted partners, Mobidiag is being able to bring fast and reliable solutions for growing demand of COVID-19 diagnostics. All of us have a role to play in the fight against this pandemic!
    Read full interview of our Instrument Team Manager Régis Melizzi.
    For more information about our coronavirus solutions, visit: https://lnkd.in/dKvxwNu

    Continue Reading